Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
One of the true biotech success stories, New York’s Regeneron has set its ambitions sky high with two blockbusters in their back pocket and some potential winners in the pipeline. But one of those bestsellers, immunology med Dupixent, hasn’t taken off quite as expected.
Despite more than three and a half years on the market and its parent companies’ pitch as a better biologic for eczema, IL-4 med Dupixent is still sitting at a meager 6% market share of its 2.2 million eligible patients in the US, Regeneron execs said on a fourth-quarter earnings call with analysts Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.